Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 February 2021 Photo UFS photo archive
The National Control Laboratory for Biological Products (NCL) Building.

There can be no compromise when it comes to the quality of medicines made available to the public.

The UFS-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA).

In its role as a vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 

International testing standards

The laboratory received the status of a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) endorsed its quality-management systems as of a high standard according to the International Standards Organisation’s requirements.

With its international testing standards, the NCL must ensure that all its operations – from the way documents are compiled and stored, to the maintenance of equipment and infrastructure, as well as staff competency – are performed according to international guidelines.

The laboratory has all the quality systems in place to ensure high-quality test results. The certificate of Good Manufacturing Compliance received in 2019 indicates that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. This certification is very strict and means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world. The certification offers the South African Health Products Regulatory Authority, the WHO, and other national control laboratories around the world the confidence that the test results from the NCL can be trusted.

Licensed as pharmaceutical manufacturer

The laboratory is also licensed as a pharmaceutical manufacturer. Although the lab does not manufacture, it needs to comply with manufacturing standards. It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications.

News Archive

CDS receives another international grant from the NIH
2015-12-11

 

Dr Carla Sharp

The Centre for Development Support (CDS) is partner to another international research grant from the National Institutes of Health (NIH) in the United States. The new project follows an earlier project funded by the NIH, which focused on the mental health of orphans and vulnerable children.

The new project is to focus on investigating possible improvements in the mental health and cognitive development of orphaned and vulnerable children aged between seven and eleven years, by means of improved community-based care in the Mangaung Township area in Bloemfontein.  The project will stretch over three years and has a budget of approximately R10 million.

“We shall use the Mediational Intervention of Sensitizing Caregivers (MISC) approach and it will be applied by community-based organisations,” says Dr Deidre van Rooyen, Acting Director of the CDS. 

MISC applied by caregivers has produced good results elsewhere in the world. “This is the first time MISC will be tested by community-based organisations,” says Prof Lochner Marais of the CDS, who is also the principal investigator in South Africa.

“In addition to working with four community-based organisations in Mangaung, Childline Free State will also be actively involved in the project,” Marais added.

The project is being conducted in collaboration with Dr Carla Sharp as principal investigator at the University of Houston, and Prof Michael Boivin (an international expert on MISC) at the Michigan State University. Dr Sharp was recently appointed visiting professor at the CDS. 

“It is indeed a great privilege to be working with the CDS on yet another project,” Dr Sharp remarked, also noting that “the project is preliminary in nature and could evolve into a much bigger research project in future”.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept